JP2013528649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528649A5 JP2013528649A5 JP2013515456A JP2013515456A JP2013528649A5 JP 2013528649 A5 JP2013528649 A5 JP 2013528649A5 JP 2013515456 A JP2013515456 A JP 2013515456A JP 2013515456 A JP2013515456 A JP 2013515456A JP 2013528649 A5 JP2013528649 A5 JP 2013528649A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- ranolazine
- administered
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 44
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims description 27
- 229960000213 ranolazine Drugs 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 19
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010008479 Chest Pain Diseases 0.000 claims description 9
- 206010013971 Dyspnoea exertional Diseases 0.000 claims description 7
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims description 4
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims description 4
- 239000000480 calcium channel blocker Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 229940124549 vasodilator Drugs 0.000 claims description 4
- 239000003071 vasodilator agent Substances 0.000 claims description 4
- 230000002861 ventricular Effects 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims description 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000021060 Pulmonary arterial hypertension associated with another disease Diseases 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 230000004872 arterial blood pressure Effects 0.000 claims description 2
- 229940097217 cardiac glycoside Drugs 0.000 claims description 2
- 239000002368 cardiac glycoside Substances 0.000 claims description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 2
- 229960005156 digoxin Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 229930002534 steroid glycoside Natural products 0.000 claims description 2
- 150000008143 steroidal glycosides Chemical class 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 229960001123 epoprostenol Drugs 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 2
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 2
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35546210P | 2010-06-16 | 2010-06-16 | |
| US61/355,462 | 2010-06-16 | ||
| US40786410P | 2010-10-28 | 2010-10-28 | |
| US61/407,864 | 2010-10-28 | ||
| PCT/US2011/040363 WO2011159706A1 (en) | 2010-06-16 | 2011-06-14 | Ranolazine for use for the treatment of pulmonary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528649A JP2013528649A (ja) | 2013-07-11 |
| JP2013528649A5 true JP2013528649A5 (enExample) | 2014-07-31 |
Family
ID=44202215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515456A Withdrawn JP2013528649A (ja) | 2010-06-16 | 2011-06-14 | 肺高血圧症の処置のために使用するためのラノラジン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120004188A1 (enExample) |
| EP (1) | EP2582372A1 (enExample) |
| JP (1) | JP2013528649A (enExample) |
| AR (1) | AR081925A1 (enExample) |
| AU (1) | AU2011267871A1 (enExample) |
| CA (1) | CA2801707A1 (enExample) |
| TW (1) | TW201215392A (enExample) |
| UY (1) | UY33453A (enExample) |
| WO (1) | WO2011159706A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040063717A1 (en) | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
| US20130245469A1 (en) * | 2012-03-19 | 2013-09-19 | Cardiomems, Inc. | Pulmonary Arterial Hemodynamic Monitoring for Chronic Obstructive Pulmonary Disease Assessment and Treatment |
| WO2014066870A1 (en) | 2012-10-26 | 2014-05-01 | The Medicines Company | Methods for controlling blood pressure and reducing dyspnea in heart failure |
| WO2014081958A1 (en) | 2012-11-21 | 2014-05-30 | Cardiomems, Inc. | Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment |
| US9198908B2 (en) | 2013-03-15 | 2015-12-01 | St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) | Methods for the treatment of cardiovascular conditions |
| KR20190005708A (ko) * | 2017-07-05 | 2019-01-16 | 이화여자대학교 산학협력단 | 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물 |
| EP4210684A4 (en) * | 2020-09-11 | 2024-10-09 | Pulmosim Therapeutics LLC | Compositions and methods for treating or preventing pulmonary hypertension |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| KR20070093988A (ko) | 2005-01-06 | 2007-09-19 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 라놀라진 함유 서방성 약제학적 제형물 |
| US20100010024A1 (en) * | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| WO2010068461A1 (en) | 2008-11-25 | 2010-06-17 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
-
2011
- 2011-06-10 TW TW100120385A patent/TW201215392A/zh unknown
- 2011-06-14 CA CA2801707A patent/CA2801707A1/en not_active Abandoned
- 2011-06-14 EP EP11726037.2A patent/EP2582372A1/en not_active Withdrawn
- 2011-06-14 UY UY0001033453A patent/UY33453A/es not_active Application Discontinuation
- 2011-06-14 AU AU2011267871A patent/AU2011267871A1/en not_active Abandoned
- 2011-06-14 AR ARP110102063A patent/AR081925A1/es unknown
- 2011-06-14 US US13/160,393 patent/US20120004188A1/en not_active Abandoned
- 2011-06-14 WO PCT/US2011/040363 patent/WO2011159706A1/en not_active Ceased
- 2011-06-14 JP JP2013515456A patent/JP2013528649A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528649A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| JP2021504423A5 (enExample) | ||
| CA3083327A1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| WO2007145941A8 (en) | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases | |
| JP2005532330A5 (enExample) | ||
| NZ592615A (en) | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| JP2002508766A (ja) | 心不全の治療方法 | |
| Schiffrin | Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature | |
| KR20180017145A (ko) | 소양증의 치료 | |
| NZ592613A (en) | Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| Wada et al. | Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure | |
| CN103582480A (zh) | 治疗肺高压的方法 | |
| Savale et al. | Current management approaches to portopulmonary hypertension | |
| JP2009532494A5 (enExample) | ||
| WU et al. | Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers | |
| JP2022540198A (ja) | 組合せ | |
| Kiss et al. | Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats. | |
| Ogawa et al. | Effects of lisinopril and nitrendipine on urinary albumin excretion and renal function in patients with mild to moderate essential hypertension | |
| Baumhäkel et al. | Current therapy of pulmonary hypertension | |
| Oh et al. | Beneficial effect of efonidipine, an L-and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild-to-moderate essential hypertension | |
| Lee et al. | The comparative clinical effects of valsartan and ramipril in patients with heart failure | |
| Doumas et al. | Endothelin receptor antagonists (ERA) in hypertension and chronic kidney disease: a rose with many thorns | |
| Kumar et al. | Drugs for Pulmonary Hypertension | |
| RU2020142051A (ru) | Способы и композиции для лечения легочной гипертензии |